SOURCE: The Bedford Report

The Bedford Report

April 12, 2011 08:16 ET

Cell Therapeutics and Sunesis Eager to Earn Blockbuster Status

The Bedford Report Provides Analyst Research on Cell Therapeutics & Sunesis Pharmaceuticals

NEW YORK, NY--(Marketwire - Apr 12, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Cell Therapeutics, Inc. (NASDAQ: CTIC) and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Access to the full company reports can be found at:

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Cell Therapeutics recently said that it will spend $10 million to buy rights to an anti-cancer drug owned by Chroma Therapeutics. Cell Therapeutics said that in trials, Chroma's drug had "demonstrated significant anti-tumor responses in blood related cancers and solid tumors."

Cell Therapeutics has its own potential blockbuster drug working its way through the regulatory process. Although the company's "pixantrone" drug for non-Hodgkin's lymphoma failed to gain FDA approval last year, CTIC is preparing to start a new clinical trial of the drug.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information